CD35 (CR1) Human siRNA Oligo Duplex (Locus ID 1378)

CAT#: SR300968

CR1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each


USD 518.00

In Stock*

Size
    • 1 kit

Product Images

Frequently bought together (3)
siTran 2.0 siRNA transfection reagent (0.5ml)
    • 500 ul

USD 271.00


Trilencer-27 Fluorescent-labeled transfection control siRNA duplex - 1 nmol
    • 1 nmol

USD 142.00


CR1 mouse monoclonal antibody,clone OTI2A8
    • 100 ul

USD 447.00

Specifications

Product Data
Purity HPLC purified
Quality Control Tested by ESI-MS
Sequences Available with shipment
Components CR1 (Human) - 3 unique 27mer siRNA duplexes - 2 nmol each (Locus ID 1378)
Included - SR30004, Trilencer-27 Universal Scrambled Negative Control siRNA Duplex - 2 nmol
Included - SR30005, RNAse free siRNA Duplex Resuspension Buffer - 2 ml
Stability One year from date of shipment when stored at -20°C.
Number of Transfections Approximately 330 transfections/2nmol in 24-well plate under optimized conditions (final conc. 10 nM).
Note Single siRNA duplex (10nmol) can be ordered.
Reference Data
RefSeq NM_000573, NM_000651
UniProt ID P17927
Synonyms C3BR; C4BR; CD35; KN
Summary This gene is a member of the receptors of complement activation (RCA) family and is located in the 'cluster RCA' region of chromosome 1. The genome is polymorphic at this locus with allele-specific splice variants encoding different isoforms, based on the presence/absence of long homologous repeats (LHRs). The gene encodes a monomeric single-pass type I membrane glycoprotein found on erythrocytes, leukocytes, glomerular podocytes, and splenic follicular dendritic cells. The Knops blood group system is a system of antigens located on this protein. The protein mediates cellular binding to particles and immune complexes that have activated complement. Decreases in expression of this protein and/or mutations in this gene have been associated with gallbladder carcinomas, mesangiocapillary glomerulonephritis, systemic lupus erythematosus, sarcoidosis and Alzheimer's disease. Mutations in this gene have also been associated with a reduction in Plasmodium falciparum rosetting, conferring protection against severe malaria. [provided by RefSeq, May 2020]
Performance Guaranteed OriGene guarantees that at least two of the three Dicer-Substrate duplexes in the kit will provide at least 70% or more knockdown of the target mRNA when used at 10 nM concentration by quantitative RT-PCR when the TYE-563 fluorescent transfection control duplex (cat# SR30002) indicates that >90% of the cells have been transfected and the HPRT positive control (cat# SR30003) provides 90% knockdown efficiency.

For non-conforming siRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the siRNA kit. To arrange for a free replacement with newly designed duplexes, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled siRNA control (quantitative RT-PCR data required).

{0} Product Review(s)

0 Product Review(s) Submit review

Be the first one to submit a review

Product Citations

*Delivery time may vary from web posted schedule. Occasional delays may occur due to unforeseen complexities in the preparation of your product. International customers may expect an additional 1-2 weeks in shipping.